HomeRopinirole

Ropinirole

Also known as: Ropinirole

Nonergot Dopamine AgonistDopamine Agonists

Route: Oral

Check Ropinirole Interactions →
13 interactions on record

Ropinirole has 13 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Metoclopramide, Metoclopramide Hydrochloride, Butyrophenones. Patients taking Ropinirole should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total
13
Contraindicated
2
Major
3
Moderate
3
Minor
5

Contraindicated (2)

Major (3)

  • Ropinirole + ButyrophenonesDopamine antagonists may diminish the effectiveness of ropinirole. Use in patients with major psychotic disorders only i
  • Ropinirole + CiprofloxacinCYP1A2 inhibitor increased ropinirole AUC by 84% and Cmax by 60%. Dose adjustment of ropinirole may be required.
  • Ropinirole + PhenothiazinesDopamine antagonists may diminish the effectiveness of ropinirole. Use in patients with major psychotic disorders only i

Moderate (3)

  • Ropinirole + EstrogensHigher doses of estrogens reduce clearance of ropinirole; starting or stopping hormone replacement therapy may require r
  • Ropinirole + Ethinyl EstradiolEstrogen that reduces oral clearance of ropinirole by 36%; starting or stopping may require dose adjustment of ropinirol
  • Ropinirole + Parathyroid HormoneHigher doses of estrogens reduce clearance of ropinirole; starting or stopping HRT may require dose adjustment.

Minor (5)

  • Ropinirole + CarbidopaCoadministration with L-dopa and ropinirole had no effect on steady-state pharmacokinetics of ropinirole.
  • Ropinirole + Carbidopa And LevodopaCo-administration had no effect on ropinirole steady-state pharmacokinetics. Ropinirole increased L-dopa Cmax by 20% but
  • Ropinirole + DigoxinCoadministration did not alter the steady-state pharmacokinetics of digoxin.
  • Ropinirole + MethyldopaCoadministration had no effect on steady-state pharmacokinetics of ropinirole; ropinirole increased mean steady-state Cm
  • Ropinirole + TheophyllineCYP1A2 substrate; coadministration did not alter steady-state pharmacokinetics of either drug.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.